Ajinomoto and Takeda Pharmaceutical Co. Ltd. Release: A Once-weekly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent, Was Approved in Japan

Published: Apr 18, 2007

Tokyo, Apr 18, 2007 (JCN Newswire) - Ajinomoto Co., Inc. ("Ajinomoto", President and CEO: Norio Yamaguchi, Headquarters: Tokyo) and Takeda Pharmaceutical Company Limited ("Takeda", President: Yasuchika Hasegawa, Headquarters: Osaka) are pleased to announce that the Ministry of Health, Labour and Welfare approved today "Actonel(R) 17.5 mg tablets" and "Benet(R) 17.5 mg tablets", a once-weekly formulation of risedronate sodium hydrate (generic name) for the treatment of osteoporosis.

Back to news